Arquer Diagnostics
CE certificate


Kit ADX Bladder

Product family:

Product family:
Molecular Oncology



MCM5 is a group of MCM proteins that is produced in cells during replication and is a novel cancer biomarker.

Proliferating cells express MCM5 protein at a high level, whilst quiescent terminally differentiated cells, and senescent cells lack MCM5 expression.

In contrast, both non-invasive and invasive urothelial carcinomas express MCM5 in all layers of the urothelium including superficial epithelial cells. This results in the exfoliation of MCM5-expressing tumour cells into the urine. Therefore the presence of MCM5 in the urine sediment is an excellent indicator of the presence of a urological tumour.


ADXBLADDER by Arquer Diagnostics delivers a simple, rapid and highly reliable diagnosis of bladder cancer from urine.

This ELISA kit has been designed for the detection of MCM5 protein in human urine for the diagnostic of bladder cancer in patients who have hematuria and symptoms in the lower urinary tract with suspected malignancy.


The negative predictive value of the Arquer MCM5 ELISA test is 98% (based on a prevalence of 8.38%).


Comparisons to alternative urine tests demonstrate that the Arquer's MCM5 ELISA kit has superior sensitivity to both NMP22 and urine cytology, with the MCM5 ELISA identifying all of the cases detected by these urine based methods.


ADXBladder - MC5001B


All the reagents required to prepare and run samples for analysis by manual or automated ELISA are included:

• One x 96 microwell plate of 12, 8 microwell strips coated with mouse monoclonal anti-MCM5 antibody

• Wash solution, 20x concentrate

• Anti-MCM5 antibody HRP conjugate

• TMB substrate reagent.

• Stop solution

• Lysis buffer /Negative Control

• Positive Control


Fill in the form below:

  • Download Kit ADX Bladder Brochure Download
If you are interested in learning more about this product, contact us

Cookies usage

We use our own and third party cookies to enhance browsing experience and deliver content and advertising. By continuing navigation we understand you accept our cookies policy.